Sjogren’s Syndrome Pipeline Assessment, 2023 Updates | in-Depth Insights Into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, and Key Companies

Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 20+ key pharma and biotech companies are working on 20+ pipeline drugs in the Sjogren’s Syndrome therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Sjogren’s syndrome therapeutics market is expected to grow significantly owing to the increasing prevalence of the disease and the launch of promising emerging pipeline therapies with a new mechanism of action in the market. Major pharma and biotech giants such as Horizon Therapeutics, Dompe Farmaceutici, PharmaMar, Novartis, Resolve Therapeutics, OSE Immunotherapeutics, and Servier, are eyeing the existing untapped Sjogren’s Syndrome market and trying their best to grab a significant therapeutics market share.

Sjogren’s Syndrome Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Sjogren’s Syndrome Market. 

The Sjogren’s Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Sjogren’s Syndrome Pipeline Analysis

The report provides insights into: 

The report provides detailed insights into the emerging therapies for the treatment of Sjogren’s Syndrome and the aggregate therapies developed by major pharma companies.

It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Sjogren’s Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) 

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates


Route of Administration

Sjogren’s Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as











Molecule Type

Products have been categorized under various Molecule types, such as


Monoclonal Antibody



Small molecule


Learn How the Ongoing Clinical & Commercial Activities will Affect the Sjogren’s Syndrome Therapeutic Segment @

Sjogren’s Syndrome Therapeutics Landscape

There are approx. 20+ key companies developing Sjogren’s Syndrome therapies. Currently, Horizon Therapeutics is leading the therapeutics market with its Sjogren’s Syndrome drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Sjogren’s Syndrome Therapeutics Market Include:

Alpine Immune Sciences

Bristol-Myers Squibb


Dompe Farmaceutici


Horizon Therapeutics




OSE Immunotherapeutics/Servier


Resolve Therapeutics



And many others

Sjogren’s Syndrome Drugs Covered in the Report Include:

CFZ533: Novartis

Lusvertikimab (formerly OSE-127): OSE Immunotherapeutics/Servier

Oxervate (cenegermin): Dompe Farmaceutici

RSLV-132: Resolve Therapeutics

Tivanisiran (SYL1001): PharmaMar

VAY736: Novartis/MorphoSys

VIB4920: Horizon Therapeutics

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Sjogren’s Syndrome Current Treatment Patterns

4. Sjogren’s Syndrome – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Sjogren’s Syndrome Late Stage Products (Phase-III)

7. Sjogren’s Syndrome Mid-Stage Products (Phase-II)

8. Sjogren’s Syndrome Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Sjogren’s Syndrome Discontinued Products

13. Sjogren’s Syndrome Product Profiles

14. Key Companies in the Sjogren’s Syndrome Market

15. Key Products in the Sjogren’s Syndrome Therapeutics Segment

16. Dormant and Discontinued Products

17. Sjogren’s Syndrome Unmet Needs

18. Sjogren’s Syndrome Future Perspectives

19. Sjogren’s Syndrome Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Strategies

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Daily Digest Signup

Daily business and market business news, business management tips, market research insights, and more.


Smart public opinion research for everyone.

Generated by Feedzy
%d bloggers like this: